These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21454223)

  • 1. Novel M-component based biomarkers in Waldenström's macroglobulinemia.
    Leleu X; Koulieris E; Maltezas D; Itzykson R; Xie W; Manier S; Dulery R; Boyle E; Gauthier J; Poulain S; Tatiana T; Panayiotidis P; Bradwell AR; Harding S; Leblond V; Kyrtsonis MC; Ghobrial IM
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):164-7. PubMed ID: 21454223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.
    Boyle E; Manier S; Lejeune J; Fouquet G; Guidez S; Bonnet S; Debarri H; Demarquette H; Dulery R; Gay J; Hennache B; Onraed B; Faucompré JL; Schraen S; Facon T; Avet-Loiseau H; Chevret S; Leblond V; Harding S; Leleu X
    Clin Cancer Res; 2016 Oct; 22(20):5152-5158. PubMed ID: 27169996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.
    Al-Katib AM; Mensah-Osman E; Aboukameel A; Mohammad R
    Semin Oncol; 2003 Apr; 30(2):313-7. PubMed ID: 12720160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
    Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U; Ferreri AJ; Montoto S
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
    Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.
    Jiménez C; Sebastián E; Chillón MC; Giraldo P; Mariano Hernández J; Escalante F; González-López TJ; Aguilera C; de Coca AG; Murillo I; Alcoceba M; Balanzategui A; Sarasquete ME; Corral R; Marín LA; Paiva B; Ocio EM; Gutiérrez NC; González M; San Miguel JF; García-Sanz R
    Leukemia; 2013 Aug; 27(8):1722-8. PubMed ID: 23446312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
    Bladé J; Montoto S; Rosiñol L; Montserrat E
    Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
    Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
    Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
    Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histidine based adsorbents for selective removal of monoclonal immunoglobulin IgM antibodies from Waldenstrom's macroglobulinemia patient sera: a preliminary study.
    Srour M; Kassab I; Matta H; Elkak A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():1-5. PubMed ID: 23811496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation.
    Walsh SH; Laurell A; Sundström G; Roos G; Sundström C; Rosenquist R
    Leuk Res; 2005 Jul; 29(7):729-34. PubMed ID: 15927667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
    Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis.
    Sacco A; Maiso P; Azab A; Azab F; Zhang Y; Liu Y; Ngo HT; Morgan B; Quang P; Issa G; Ghobrial IM; Roccaro AM
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):109-11. PubMed ID: 21454206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of bone marrow response in Waldenström's macroglobulinemia.
    Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.